#USA #Phoenixville #Sleep Quality #PleoPharma #Cannabis Use Disorder

PleoPharma, Inc. Secures New Patent for Sleep Quality Improvement

PleoPharma, Inc., a privately owned entity specializing in cannabis-related health innovations, has announced the issuance of a groundbreaking patent focused on improving treatment options for individuals enduring sleep disturbances associated with cannabis withdrawal syndrome (CWS). This announcement comes as part of the company's ongoing efforts to address the challenges posed by cannabis use disorder (CUD), which has become increasingly prevalent in recent years.

New Patent Issuance

On April 8, 2025, the U.S. Patent Office granted PleoPharma a new patent that further strengthens its intellectual property portfolio in the realm of cannabis health treatments. This patent outlines methods for alleviating symptoms of CWS, particularly those affecting sleep quality, depth, and duration. According to the company's CEO, Dr. Ginger Constantine, the significance of this advancement cannot be overstated. "Improving sleep for patients suffering from CWS is crucial for enhancing their quality of life," she stated, emphasizing the company's commitment to providing innovative solutions for this challenging population.

This latest patent, numbered 12,268,659, details specific dosing regimens and methods for using PP-01, PleoPharma’s lead asset, which aims to tackle the complications posed by CUD. Notably, this development aligns with the broader goal of offering effective treatments where options have previously been limited.

The Significance of Cannabis Use Disorder

According to government statistics from 2023, approximately 19.2 million Americans are affected by CUD, with a notable figure of roughly 1.64 million people actively receiving treatment. The rising trend of individuals seeking help for cannabis-related health concerns reflects a growing awareness and recognition of the potential dependencies associated with cannabis use. Such statistics underscore the urgency for effective treatment modalities aimed at mitigating withdrawal symptoms associated with CWS.

Cannabis Withdrawal Syndrome can manifest through a variety of distressing symptoms, including significant disruptions to sleep patterns. As many patients struggle with the psychological and physiological impacts of withdrawal, the ability to ensure restful sleep is a cornerstone of their recovery process. Until now, no FDA-approved treatments have existed for CWS or CUD, making PleoPharma's efforts particularly vital.

Company Mission and Future Outlook

PleoPharma's overarching mission is to develop solutions tailored for individuals who wish to reduce or discontinue cannabis use responsibly. Understanding that some users engage with cannabis without complications, PleoPharma is determined to create pathways for those who may encounter dependency issues.

In addition to the recent patent, the company has other applications pending both domestically and internationally, indicating a proactive approach to expanding their intellectual property and solidifying their market position. PleoPharma boasts a seasoned team with a history of success in the biotech sector, having facilitated various high-stakes product approvals and clinical advancements.

Conclusion

With the issuance of this new patent, PleoPharma is not just enhancing its product offerings; it is also taking a significant step toward improving the lives of millions affected by cannabis-related health issues. The potential to create a meaningful impact in the field of addiction treatment is profound, as the company continues to work towards the first FDA-approved treatment for CWS associated with CUD. Those interested in following PleoPharma's journey can visit their official website for further updates and information.